/ICLR
ICLR Stock - ICON Public Limited Company
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$173.77-2.76%
$4.93 (-2.76%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).92
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+20.8%upside
Target: $209.91
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ICLR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$172.03 – $175.51
TARGET (TP)$210.00
STOP LOSS$159.87
RISK/REWARD1:2.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.25
52W High$228.29
52W Low$125.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.28B | $8.12B | $7.74B | $5.48B | $2.80B |
| Gross Profit | $2.44B | $2.40B | $2.21B | $1.51B | $808.03M |
| Gross Margin | 29.4% | 29.6% | 28.6% | 27.5% | 28.9% |
| Operating Income | $1.10B | $956.15M | $795.24M | $378.53M | $391.50M |
| Net Income | $791.47M | $612.34M | $505.30M | $153.19M | $327.81M |
| Net Margin | 9.6% | 7.5% | 6.5% | 2.8% | 11.7% |
| EPS | $9.60 | $7.46 | $6.20 | $2.28 | $6.29 |
Company Overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
50%
Hold / Neutral
11
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
11 Bullish11 Neutral/Bearish
Price Targets
$252
Average Target
↑ 44.8% Upside
Now
$150
Low
$252
Average
$379
High
Based on 23 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | BofA Securities | Downgrade | Neutral | $195 |
| November 13th 2025 | BMO Capital Markets | Initiation | Market Perform | $175 |
| September 9th 2025 | Jefferies | Downgrade | Hold | $175 |
| September 3rd 2025 | Rothschild & Co Redburn | Upgrade | Buy | $236 |
| August 21st 2025 | Citigroup | Downgrade | Neutral | $200 |
| July 24th 2025 | Robert W. Baird | Upgrade | Outperform | $224 |
| April 29th 2025 | JP Morgan | Downgrade | Neutral | $150 |
| April 14th 2025 | TD Cowen | Downgrade | Hold | $157 |
| April 10th 2025 | Barclays | Downgrade | Equal Weight | $165 |
| March 21st 2025 | Goldman | Downgrade | Neutral | $200← $250 |
| January 7th 2025 | RBC Capital Mkts | Initiation | Outperform | $263 |
| October 24th 2024 | Robert W. Baird | Downgrade | Neutral | $340 |
| October 14th 2024 | Redburn Atlantic | Initiation | Neutral | - |
| September 18th 2024 | Leerink Partners | Initiation | Outperform | $379 |
| June 6th 2024 | Goldman | Initiation | Buy | $370 |
Earnings History & Surprises
ICLRBeat Rate
83%
Last 18 quarters
Avg Surprise
+0.6%
EPS vs Estimate
Beats / Misses
15/2
1 met exactly
Latest EPS
$3.31
Q4 2025
EPS Surprise History
Q1 24
+0.6%
$3.46vs$3.44
Q2 24
+1.8%
$3.47vs$3.41
Q3 24
+1.9%
$3.75vs$3.68
Q4 24
-13.0%
$3.35vs$3.85
Q1 25
+0.6%
$3.43vs$3.41
Q2 25
+2.6%
$3.19vs$3.11
Q3 25
+2.2%
$3.26vs$3.19
Q4 25
+0.9%
$3.31vs$3.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $3.34 | — | — | — |
Q4 2025 | Oct 22, 2025 | $3.28 | $3.31 | +0.9% | ✓ BEAT |
Q3 2025 | Jul 23, 2025 | $3.19 | $3.26 | +2.2% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $3.11 | $3.19 | +2.6% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $3.41 | $3.43 | +0.6% | ✓ BEAT |
Q4 2024 | Oct 23, 2024 | $3.85 | $3.35 | -13.0% | ✗ MISS |
Q3 2024 | Jul 24, 2024 | $3.68 | $3.75 | +1.9% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $3.41 | $3.47 | +1.8% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $3.44 | $3.46 | +0.6% | ✓ BEAT |
Q4 2023 | Oct 25, 2023 | $3.28 | $3.30 | +0.6% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $3.08 | $3.11 | +1.0% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $2.98 | $2.90 | -2.7% | ✗ MISS |
Q1 2023 | Feb 22, 2023 | $3.06 | $3.13 | +2.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $2.93 | $3.00 | +2.4% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $2.79 | $2.86 | +2.5% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $2.71 | $2.76 | +1.8% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $2.63 | $2.63 | 0.0% | = MET |
Q4 2021 | Nov 3, 2021 | $2.43 | $2.55 | +4.9% | ✓ BEAT |
Q3 2021 | Jul 21, 2021 | $2.10 | $2.12 | +1.0% | ✓ BEAT |
Latest News
BMO Capital Initiates Coverage On Icon with Market Perform Rating, Announces Price Target of $175
➖ NeutralBenzinga•Nov 13, 2025, 09:35 AM
TD Cowen Maintains Hold on Icon, Lowers Price Target to $172
📉 NegativeBenzinga•Oct 24, 2025, 04:44 PM
ICON shares are trading lower after the company reported Q3 financial results and narrowed its FY25 adjusted EPS guidance below estimates.
📉 NegativeBenzinga•Oct 22, 2025, 08:33 PM
Icon Narrows FY2025 Adj EPS Guidance from $13.00-$14.00 to $13.00-$13.20 vs $13.22 Est; Narrows FY2025 Sales Guidance from $7.850B-$8.150B to $8.050B-$8.100B vs $7.977B Est
📈 PositiveBenzinga•Oct 22, 2025, 08:28 PM
Icon Q3 Adj. EPS $3.31 Beats $3.29 Estimate, Sales $2.043B Beat $1.983B Estimate
📈 PositiveBenzinga•Oct 22, 2025, 08:26 PM
Jefferies Downgrades Icon to Hold, Lowers Price Target to $175
📉 NegativeBenzinga•Sep 9, 2025, 10:57 AM
ICON Plc Confirms That There Is No Change To Its Financial Guidance For FY 2025
➖ NeutralBenzinga•Sep 4, 2025, 01:42 PM
ICON shares are trading lower after the company announced its CEO will retire.
📉 NegativeBenzinga•Sep 4, 2025, 01:12 PM
ICON CEO Dr. Steve Cutler To Retire; COO Barry Balfe Appointed As Successor, Effective October 1, 2025
➖ NeutralBenzinga•Sep 4, 2025, 12:12 PM
Baird Maintains Outperform on Icon, Raises Price Target to $224
📈 PositiveBenzinga•Sep 2, 2025, 03:22 PM
Shares of vaccine companies are trading lower following a Daily Beast report suggesting that President Trump and Health and Human Services Robert F. Kennedy, Jr. will ban Covid-19 vaccines "within months.
📉 NegativeBenzinga•Aug 25, 2025, 05:50 PM•Also: , ,
Frequently Asked Questions about ICLR
What is ICLR's current stock price?
ICON Public Limited Company (ICLR) is currently trading at $173.77 per share. The stock has moved -2.76% today.
What is the analyst price target for ICLR?
The average analyst price target for ICLR is $210.00, based on 1 analyst.
What sector is ICON Public Limited Company in?
ICON Public Limited Company operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is ICLR's market cap?
ICON Public Limited Company has a market capitalization of $13.27 billion, making it a large-cap company.
Does ICLR pay dividends?
No, ICON Public Limited Company does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOO
The Cooper Companies, Inc.
$82.75
Mkt Cap: $16.5B
EHC
Encompass Health Corporation
$106.39
Mkt Cap: $10.7B
EXAS
Exact Sciences Corporation
$101.82
Mkt Cap: $19.3B
GH
Guardant Health, Inc.
$99.74
Mkt Cap: $12.4B
MEDP
Medpace Holdings, Inc.
$568.36
Mkt Cap: $16.0B
NBIX
Neurocrine Biosciences, Inc.
$145.00
Mkt Cap: $14.4B
QGEN
Qiagen N.V.
$45.58
Mkt Cap: $9.9B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
SOLV
Solventum Corporation
$81.59
Mkt Cap: $14.2B
UHS
Universal Health Services, Inc.
$227.46
Mkt Cap: $14.7B
Explore stocks similar to ICLR for comparison